Breaking News: Study Validates Aureon Technology to Predict Prostate Cancer Metastasis & Progression

July 7, 2009 - PRLog -- OneMedPlace interviewed Aureon Laboratories, President and CEO, Vijay Aggarwal in a video news release: http://www.onemedplace.com/

OneMedPlace congratulates Aureon Laboratories, Inc., a specialized laboratory dedicated to advancing personalized cancer treatment through predictive pathology, on the cancer study published in the July 2009 issue of the Journal of Urology.  The study demonstrates that Aureon’s patented approach of integrating morphometry and biomarker data with clinical information improves accuracy for identifying which patients are most likely to develop disease progression post-surgery.

The study published in the Journal of Urology assessed the accuracy of applying a multivariate approach to determine patient risk.  Five institutions from the US and Europe collaborated to provide prostate needle biopsy samples from 1,027 patients who were treated with surgery and followed for a median of 8 years.   The study, using morphometry and biology, identified a panel of biopsy and patient characteristics that more accurately stratifies risk with respect to clinical outcome (67% improvement over clinical judgment and 233% better than Gleason score).  This is most evident for patients in the low- to intermediate-risk range where clinical variables alone are limited.

The abstract for the study “Personalized Prediction of Tumor Response and Cancer Progression on Prostate Needle Biopsy” can be located at www.jurology.com or at www.aureon.com.

About Aureon Laboratories:

Aureon Laboratories' mission is to enable personalized patient care through predictive pathology. Aureon has developed a high throughput systems pathology technology platform to predict individual clinical outcomes through the interrogation of tissue. The platform generates and analyzes an integrated, digital view of clinical findings, tissue micro-anatomy and tissue molecular pathology to determine which combination of features predicts specified individual clinical outcomes. Allied with major cancer centers, Aureon operates a CLIA-certified and CAP-accredited laboratory that provides predictive pathology services to the practicing physician. For more information about Aureon, please visit http://www.onemedplace.com/database/list/cid/7131/ or call 1-888-SYS-PATH.

# # #

OneMedPlace is a communications platform for healthcare and life sciences companies to connect with investors, strategic partners, and customers.